Development of the Commercial Manufacturing Process for Xanomeline Tartrate, an Active Pharmaceutical Ingredient in KarXT

待确认 10 由陌上花开发布于 2026/11/4 17:43:09

DOI:10.1021/acs.oprd.6c00185
作者：Joseph Ryan,?Aida Ajaz,?Rajender Vemula,?Christopher R. H. Hale,?Giorgio Attardo,?MVRCH Murthy,?Yolanda Gasanz,?Vijaya B. Gondi
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Development of the commercial manufacturing strategy and process employed for xanomeline tartrate (KTX-001), a key active pharmaceutical ingredient (API) in KarXT, is described. The devel

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

23小时前

pmeng

07f02f59d83511f18fb7208810ba6e4f.pdf

23小时前

Book学术机器人

2026/11/4 17:43:09 未找到该文献，机器人已退出，请等待人工下载

2026/11/4 17:43:09 Book学术AI机器人收到请求，开始寻找文献

2026/11/4 17:43:09 已向机器人发送请求

23小时前

陌上花开发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierMandatory versus voluntary: The real effect of ESG disclosures on corporate earnings management